ALLK
Closed
Allakos Inc
0.33
0.00 (0.00%)
Last Update: 15 May 2025 16:30:00
Yesterday: 0.3291
Day's Range: 0.33 - 0.33
Send
sign up or login to leave a comment!
When Written:
4.45
Allakos Inc is a clinical-stage biotechnology company that focuses on developing therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company was founded in 2012 and is headquartered in San Carlos, California.
Allakos is primarily focused on developing antibodies that target the Siglec-8 pathway, which is involved in the regulation of eosinophils, a type of white blood cell that plays a key role in allergic and inflammatory diseases. The company's lead product candidate, AK002, is a monoclonal antibody that targets Siglec-8 and is being developed for the treatment of eosinophilic gastritis and eosinophilic esophagitis, two rare gastrointestinal disorders.
Allakos has also developed a pipeline of other product candidates targeting various allergic and inflammatory diseases, including asthma, chronic urticaria, and atopic dermatitis. The company has partnerships with several pharmaceutical companies, including Regeneron and Pfizer, to develop and commercialize its product candidates.
Allakos went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol "ALLK."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Allakos is primarily focused on developing antibodies that target the Siglec-8 pathway, which is involved in the regulation of eosinophils, a type of white blood cell that plays a key role in allergic and inflammatory diseases. The company's lead product candidate, AK002, is a monoclonal antibody that targets Siglec-8 and is being developed for the treatment of eosinophilic gastritis and eosinophilic esophagitis, two rare gastrointestinal disorders.
Allakos has also developed a pipeline of other product candidates targeting various allergic and inflammatory diseases, including asthma, chronic urticaria, and atopic dermatitis. The company has partnerships with several pharmaceutical companies, including Regeneron and Pfizer, to develop and commercialize its product candidates.
Allakos went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol "ALLK."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!